Researchers presented early human clinical work exploring an immune-engineered, allogeneic insulin-producing cell therapy approach for type 1 diabetes at the ISSCR 2026 Annual Meeting. The program focuses on hypoimmune-engineered cells designed to reduce or eliminate the need for lifelong immunosuppression. The study frames a central barrier in islet replacement and beta-cell replacement therapies: sustained immune tolerance without chronic immunosuppressive regimens. The first human data timing is positioned as a meaningful milestone for cell-therapy companies targeting durable insulin independence while managing safety and immune dynamics.